The French biotechnology company Oncodesign announced the effective transfer of François Hyafil Research Centre (FHRC) from GSK and the appointment of two new activity directors, after the agreement for its acquisition signed in September 2016. The facilities have a total surface of 11,000m² and have been largely rebuilt as new in 2010. The deal included scientific equipment and the team of 57 employees, 47 of which are highly qualified scientists specialising in drug discovery. The transfer was accompanied € 35 million to be paid by GSK to Oncodesign over four years, subject to the continued employment of the transferred employees during this period
Dr Fabrice Viviani, will be the new Head of FHRC and Oncodesign’s Experimentation Director, while Dr Alexis Denis will assume the role of Discovery Director. The Executive Committee of the company is chaired by Philippe Genne. They will work under the direction of Oncodesign’s Chief Scientific Officer, Jan Hoflack.